This content is only available within our institutional offering.
06 Dec 2019
ROCHE | Roche Diagnostics: Behind The Curtain | BUY - TOP PICKS, FV CHF350 vs. 340
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
ROCHE | Roche Diagnostics: Behind The Curtain | BUY - TOP PICKS, FV CHF350 vs. 340
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
06 Dec 2019 -
Author:
Eric Le Berrigaud -
Pages:
32
A continuous trend of portfolio refocusing has been visible in the pharmaceuticals industry over recent years, including significant spin-offs. In most cases, the trend has created tremendous value for the originators and their shareholders. We assume that Roche has carefully observed this and that it may now participate.